The rapid RNA testing kits market demonstrates substantial growth potential for the upcoming ten years because of molecular diagnostic breakthroughs advancing access to quick and precise testing solutions. The market prediction shows a USD 6.7 billion value in 2025 that will grow to USD 13.4 billion by 2035 at a CAGR rate of 7.2%.
Rapid RNA testing kits exist as essential components for health facilities used to detect viral infections incorporating COVID-19 and various other RNA-based assays through fast diagnostic functions. Market expansion seems likely because point-of-care diagnosis combined with better patient results requires faster diagnosis capabilities.
Market growth for rapid diagnostic solutions in hospitals as well as clinics and remote locations will receive additional momentum from the increasing burden of infectious diseases along with the need for speed when making diagnoses.
Market Metrics
| Metric | Value |
|---|---|
| Market Size (2025E) | USD 6.7 Billion |
| Market Value (2035F) | USD 13.4 Billion |
| CAGR (2025 to 2035) | 7.2% |
The rapid RNA testing kits market shows dominance in North America because healthcare facilities embrace new technology while investing heavily in infrastructure and requiring quick diagnostic tools for responding to worldwide health emergencies including COVID-19.
The market will continue to grow because of the well-established healthcare sector mixed with leading molecular diagnostic companies operating in the area. The market potential gets strengthened through expanding home-based testing and telemedicine practices.
The European rapid RNA testing market is showing growth as multiple nations take steps to enhance their disease diagnosis abilities as part of suppressing infectious disease spread. This market sector demonstrates strong growth potential because medical facilities need quick testing solutions for their clinical operations and because hospitals advocate point-of-care diagnostics.
The Region experiences expanded market prospects due to two factors i.e. personalized medicine development alongside rising numbers of health-conscious consumers who demand accurate timely tests.
Asia Pacific is anticipated to be a region where the rapid RNA testing kits market grows incredibly. An increase in healthcare infrastructure, an increase in monetary allocation to healthcare, and an increase in public awareness about the importance of rapid diagnosis will propel the growth in the Asia-Pacific.
China, India, and Japan, the most developed countries, are now rushing into advanced RNA testing solutions, and, for that matter, active work has gone into creating and building healthcare systems to combat infectious diseases. On the other hand, chronic diseases and increased attention to proactive health measures form the basis for the market being uplifted in this region.
Cost and Accessibility
One of the major challenges posed before the market for rapid RNA testing kits is the pricing of these modern testing solutions, especially in low- and middle-income settings. While they are indeed quite useful for rapid-diagnosing infectious diseases, the kits for RNA testing remain unaffordable, especially in resource-constrained settings. Added to these are regulatory constraints and the need for specialized equipment for testing, limiting access to the market in certain regions.
Technological Advancements and Expanding Applications
Technological progress, including more compact, portable, and user-friendly RNA testing kits, provides a great opportunity to the said market. These kits would find greater utility and ease of use with the incorporation of smartphones as well as cloud-based data management systems, particularly for remote monitoring and diagnostics.
Demand for such kits will continue to be driven by infectious diseases and future pandemic threats. The broadening of RNA testing applications for genetic research, cancer detection, and personalized medicine offers an array of growth opportunities throughout the forecast period.
Between 2025 and 2035, the rapid RNA testing kits marketwould grow at a very high pace due to novel advances in molecular diagnostics, as well as the rising demand for rapid-accurate disease diagnosis, pushed by the point-of-care testing (POCT) solutions. Among infectious diseases, the developments in rapid RNA test kit innovation for the COVID-19 pandemic have paved the way for the eventual widespread application of rapid RNA test kits.
Speed, accuracy, and convenience provide compelling use cases for the clinical and nonclinical setting applications of rapid RNA tests. Rapid RNA testing kits will become more adopted as the healthcare systems of the future focus more on decentralization and delivery diagnostics beyond the typical laboratory walls.
All are specifically infections, such as seasonal flu, respiratory diseases, and emerging pathogens, among other diseases, which are highly increasing give rise to this adoption. Further, improvements in RNA technology and increased sensitivity of diagnostic testing would continue to broaden application possibilities. Finally, rapid RNA testing kits would find juggernauts in the food safety and environment monitoring business.
Market Shifts: 2020 to 2024 vs. 2025 to 2035
| Key Dimensions | 2020 to 2024 |
|---|---|
| Growth Drivers | COVID-19 pandemic, urgent need for point-of-care diagnostics |
| Technology Trends | PCR-based kits, CRISPR-based diagnostics, LAMP-based tests |
| Application Focus | Respiratory infections, viral diseases, COVID-19 |
| End-User Adoption | Hospitals, clinics, home healthcare, testing laboratories |
| Geographic Demand | North America, Europe, Asia-Pacific |
| Regulatory Landscape | FDA approvals for COVID-19 and other virus detection kits |
| Innovation Focus | Development of faster, more accurate kits |
| Supply Chain Dynamics | Centralized manufacturing for mass production of COVID-19 kits |
| Key Dimensions | 2025 to 2035 |
|---|---|
| Growth Drivers | Expanding applications in infectious diseases, food safety, environmental monitoring |
| Technology Trends | AI-enhanced diagnostics, improved sensitivity, non-invasive RNA testing |
| Application Focus | Widespread use in diagnostics, food safety, environmental monitoring, public health |
| End-User Adoption | Broader adoption in field testing, public health organizations, and consumer settings |
| Geographic Demand | Increased adoption in Latin America, Middle East, and Africa |
| Regulatory Landscape | Stricter regulatory frameworks for accuracy, portability, and data management |
| Innovation Focus | Miniaturization of testing devices, integration with IoT, and real-time analytics |
| Supply Chain Dynamics | Decentralized production, regional manufacturing hubs, and direct-to-consumer distribution models |
The market for rapid RNA testing kits in the USA seems to be rapidly evolving due to rapid demand for fast and accurate diagnosis solutions, boosted primarily by COVID-19. The increasing needs for on-site testing in healthcare facilities, airports, as well as other public sectors have fueled market growth. Increasing evolution in RNA-based diagnostics technology owing to the high level of investment in research and development also brings rapid adoption of RNA testing kits.
| Country | CAGR (2025 to 2035) |
|---|---|
| United States | 8.5% |
The market for rapid RNA testing kits is on an upward trend in the countries within the United Kingdom due to the prevalent growth in rapid diagnostic tests in health care, particularly in their application in infectious diseases. The increasing demand and trend for rapid testing kits continue to be made stronger since the advent of COVID-19, opening doors for adopting RNA testing for other infectious diseases or health conditions.
In addition, vigorous government backup for innovative technologies in diagnostics and a healthy market infrastructure tend to account for growth in the market.
| Country | CAGR (2025 to 2035) |
|---|---|
| United Kingdom | 7.5% |
The European Union has a stable growth of the rapid RNA testing kits marketas a result of the speedy yet accurate diagnoses. An additional support is that this market enjoys investments from the EU towards healthcare and diagnostics. The other contributor to this is the rising acceptability for point-of-care testing technologies.
Rapid tests for detecting infectious diseases, including COVID-19, influenza, and several other RNA-based infections in different locations such as hospitals, clinics, and airports, form the major driving factor of this market in Europe.
| Country | CAGR (2025 to 2035) |
|---|---|
| European Union | 7.3% |
The market for rapid RNA testing kits in Japan is on the rise due to the increasing incidence of contagious diseases and hence, the emphasis placed by Japan on innovating the healthcare system. An advanced healthcare infrastructure and rapid adoption of new technologies by Japan equipped the country for the increasing demand for rapid RNA testing solutions. Such enhanced diagnostic solutions by the governments in the public health and emergency response modes also add to the growth of the market.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 6.5% |
The rapid RNA testing kits marketin South Korea has been growing at a steady pace, mainly because of the demand for quick and reliable diagnostic solutions. The attention that the country pays to public health responses, especially in the wake of the COVID-19 pandemic, has intensified the use of RNA testing kits. Apart from that, the long-from advances that South Korea makes in biotechnology and diagnostics are still having an ongoing impact on the growth of this market.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 7.0% |
The rapid RNA testing kits market is certain to witness a phenomenal growth from 2025 to 2035 mainly due to the increasing demand for quick and accurate detection of viral infections caused by adenovirus, herpes virus and influenza.
Rapid RNA testing is another area seeing heavy growth and is critical to improved detection of viral infections- as shown by recent world health issues- which raised the need in both clinical and research settings. With newer and important testing technologies, the market is set to widen over multiple fronts-pharmaceutical, diagnostics, and academia.
Influenza A & B Testing Kits to Lead the Market
| Product Type | Market Share |
|---|---|
| Influenza A & B Testing Kits | 38.7% |
It is anticipated that segment Influenza A and B testing kits will have the leading share in the Rapid RNA Testing kit market with a share of 38.7% during 2025. This segment is deemed invaluable for rapid diagnosis and timely treatment of influenza infections especially during seasonal outbreaks. Driving global incidences of influenza leading to a further requirement for speedy response during flu epidemics are some of the factors influencing the market for testing kits.
Influenza A & B Testing Kits, besides their usage in the need for immediate diagnosis apart from seasonal flu, could also gain in demand by - besides being used in differentiation - rapid need for identification from other respiratory infections. Besides improving public service health responses to influenza pandemics-there is now a concern for timely diagnoses which reduce healthcare costs, hence creating avenues for increasing the growth of the market.
Pharmaceutical & Biotech Companies to Hold the Largest Share
| End-User | Market Share |
|---|---|
| Pharmaceutical & Biotech Companies | 45.3% |
The segment of Pharmaceutical and Biotech Companies is hypothesized to take hold of nearly 45.3% of the market share of the Rapid RNA Testing Kits Market by 2025. The use of RNA testing kits has gained significance in research, the development of drugs, and clinical trials in relation to virus detection and the manufacture of antiviral drugs and vaccines.
Innovative treatment, vaccines, and diagnostics still propel demand from the pharmaceuticals and biotechnology sector segments, which form important elements in this market. Growth in the need for rapid RNA testing will still fuel demand from this sector for drug formulations, clinical trials, and genetics research.
The growth of the rapid RNA testing kits market is expected to be remarkable between 2025 and 2035, with major factors including the need for speed in accurate diagnostics of infectious diseases, genetic disorders, and other health conditions.
Rapid RNA testing kits, therefore, are becoming popular not just in the clinical setup but also in hospitals and research institutions as point-of-care (POC) testing is being adopted, and healthcare is becoming decentralized. Such kits produce results much faster than PCR testing methods, making them key for early detection, personalized medicine, and real-time monitoring of disease outbreaks. The market has also been stimulated in response to the need to rapidly act on public health emergencies, as seen during the COVID-19 pandemic.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Abbott Laboratories | 18-22% |
| Roche Diagnostics | 16-20% |
| Thermo Fisher Scientific | 12-16% |
| Bio-Rad Laboratories | 10-14% |
| Cepheid (A Danaher Company) | 8-12% |
| Other Companies (combined) | 30-35% |
| Company Name | Key Offerings/Activities |
|---|---|
| Abbott Laboratories | In 2024, Abbott launched a next-generation rapid RNA testing kit for the detection of respiratory viruses, expanding its diagnostic portfolio. The company plans to expand its offerings in 2025 with RNA testing kits for genetic disorders and emerging infectious diseases. |
| Roche Diagnostics | Roche introduced an innovative rapid RNA test in 2024, designed for use in both clinical laboratories and point-of-care settings. The company is expected to enhance its product line in 2025 by introducing multi-target RNA testing kits for broader applications. |
| Thermo Fisher Scientific | Thermo Fisher expanded its portfolio in 2024 with rapid RNA detection kits for viral infections. In 2025, Thermo Fisher plans to introduce mobile RNA testing kits aimed at enhancing field testing capabilities for research and diagnostic purposes. |
| Bio-Rad Laboratories | Bio-Rad launched a rapid RNA testing kit in 2024 that offers high sensitivity and speed in detecting genetic mutations. In 2025, Bio-Rad is expected to introduce RNA testing kits designed for early detection of cancers and genetic predispositions. |
| Cepheid (A Danaher Company) | Cepheid introduced a rapid RNA testing kit in 2024 for infectious diseases with results in less than an hour. In 2025, Cepheid plans to enhance its portfolio with RNA testing solutions for pathogen surveillance and personalized medicine applications. |
Key Company Insights
Abbott Laboratories (18-22%)
Abbott remains a leader in the rapid RNA testing market, with a strong portfolio of diagnostic solutions that are widely used in both clinical and emergency settings. The company’s commitment to developing easy-to-use, rapid testing solutions will continue to support its market dominance.
Roche Diagnostics (16 to 20%)
Roche is known for its expertise in molecular diagnostics and is expanding its rapid RNA testing offerings. With a focus on precision and innovation, Roche is poised to maintain a strong position in the market with its cutting-edge RNA testing technologies.
Thermo Fisher Scientific (12-16%)
Thermo Fisher is capitalizing on the growing demand for rapid diagnostic solutions. Its focus on improving RNA detection techniques and expanding testing options for a variety of pathogens is expected to strengthen its market presence.
Bio-Rad Laboratories (10-14%)
Bio-Rad is focusing on rapid RNA testing for genetic applications, with a strong emphasis on high sensitivity and reliability. The company’s portfolio continues to grow as it looks to capture a larger share of the market by addressing unmet needs in genetics and personalized medicine.
Cepheid (A Danaher Company) (8-12%)
Cepheid is recognized for its rapid PCR technology and is expanding its offerings into the RNA testing space. With a commitment to providing rapid, accurate testing, the company is set to continue leading innovations in the molecular diagnostics field.
Other Key Players (30-35% Combined)
The overall market size for the rapid RNA testing kits market was USD 6.7 billion in 2025.
The market is expected to reach USD 13.4 billion in 2035.
Demand for rapid RNA testing kits will be driven by advancements in molecular diagnostics, increasing applications in infectious disease detection, the growing need for fast and accurate testing in clinical settings, and the rising demand for personalized medicine.
The top 5 contributing countries are the United States, China, Germany, the United Kingdom, and India.
The infectious disease diagnostic kits segment is expected to lead due to the increasing prevalence of diseases like COVID-19, influenza, and other viral infections that require fast RNA testing.
Explore In-vitro Diagnostics Devices Insights
Rapid RNA testing kits Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
